… Oral afatinib had a manageable tolerability profile. EGFR-mediated adverse … afatinib is a
valuable new option for use in treatment-naïve or EGFR TKI-naïve patients with advanced lung …

… afatinib versus chemotherapy. In the second-line treatment of advanced squamous non-small
cell lung cancer (NSCLC), afatinib … , regardless of EGFR mutation status (LUX-Lung 8 trial). …

… Lung cancer is the second most common cancer and the leading cause of cancer-related
deaths in both men and … Non–small cell lung cancer (NSCLC) is the most common form of lung …

… versus chemotherapy as first-line treatment in EGFR-mutant lung cancer LUX-Lung 3
and LUX-Lung 6 evaluated the use of afatinib versus chemotherapy in first-line treatment in …

… The aim of the present article is to critically review the clinical trials exploring afatinib efficacy
in lung cancer and to compare, when possible, this novel agent to available treatments. …

… use of afatinib. To gain a broader understanding of the effectiveness and safety of first-line
afatinib, … of real-world studies that have assessed its use in a variety of patient populations. We …

… in the ongoing studies in patients with EGFR-mutant lung cancer and acquired resistance
to erlotinib or gefitinib. The decision to use afatinib as a frontline treatment for EGFR-mutant …

… Afatinib also demonstrated activity in mouse xenograft models of either squamous NSCLC …
or lung cancer expressing altered HER2 (mutations/amplifications) [11]. The activity of afatinib …

… in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials
of afatinib in EGFR mutation-positive lung cancer. J Thorac Oncol 2013;8(Suppl):abstract O03…

… Afatinib is also active in patients progressing on EGFR tyrosine … afatinib within a
compassionate-use program (CUP). … of action of afatinib on lung cancers depending on mutant …